Ondansetron in pregnancy and risk of adverse fetal outcomes in the United States

被引：34
|
作者：
Fejzo, Marlena S. [1 ,3 ]
MacGibbon, Kimber W. [2 ]
Mullin, Patrick M. [3 ]
机构：
[1] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA
[2] Hyperemesis Educ & Res Fdn, Damascus, OR USA
[3] Univ So Calif, Keck Sch Med, Dept Maternal Fetal Med, Los Angeles, CA 90033 USA
来源：
REPRODUCTIVE TOXICOLOGY | 2016年 / 62卷
关键词：
Ondansetron; Hyperemesis gravidarum; Pregnancy; Nausea; Birth defect; Morning sickness; Heart defect; Cleft; NAUSEA;
D O I：
10.1016/j.reprotox.2016.04.027
中图分类号：
Q [生物科学];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
This is an analysis of fetal outcome in pregnancies exposed to ondansetron to treat Hyperemesis Gravidarum (HG). In this retrospective cohort study, U.S. data on outcome were collected on 1070 pregnancies exposed to ondansetron and compared to outcomes in two control groups: 771 pregnancies in women with a history of HG with no ondansetron exposure and 1555 pregnancies with neither a history of HG nor ondansetron exposure. Ventricular septal defects were reported in 2/952 of infants in the HG/Ondansetron-exposure group and 4/1286 in the No HG/No Ondansetron-exposure group. Cleft palate was reported in 1/952 live births in the HG/Ondansetron and 2/1286 in the No HG/No Ondansetron-exposure groups. Women with a history of HG who took ondansetron reported less miscarriages and terminations, and higher live birth rates. The overall results do not support evidence of teratogenicity of ondansetron. (C) 2016 Elsevier Inc. All rights reserved.
引用
收藏
页码：87 / 91
页数：5
相关论文
共 50 条
  • [1] Ondansetron in pregnancy and risk of adverse fetal outcomes in the United States
    Reichmann, James P.
    REPRODUCTIVE TOXICOLOGY, 2016, 66 : 122 - 122
  • [2] Ondansetron in pregnancy and risk of adverse fetal outcomes in the United States Comment
    White, Tacey
    Williams, Amy
    DeSesso, John M.
    REPRODUCTIVE TOXICOLOGY, 2016, 66 : 124 - 125
  • [3] Ondansetron in pregnancy and risk of adverse fetal outcomes in the United States Response
    Sweeting, J. Nicole
    Wells, Peter G.
    REPRODUCTIVE TOXICOLOGY, 2016, 66 : 126 - 127
  • [4] Ondansetron in pregnancy and risk of adverse fetal outcomes in the United States Response
    Fejzo, Marlena
    MacGibbon, Kimber
    Mullin, Patrick
    REPRODUCTIVE TOXICOLOGY, 2016, 66 : 123 - 123
  • [5] Ondansetron in Pregnancy and Risk of Adverse Fetal Outcomes
    Pasternak, Bjorn
    Svanstrom, Henrik
    Hviid, Anders
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (09): : 814 - 823
  • [6] Ondansetron Use in Pregnancy and Risk of Adverse Fetal Outcomes
    Pasternak, Bjorn
    Svanstrom, Henrik
    Hviid, Anders
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2013, 22 : 14 - 14
  • [7] Ondansetron in pregnancy, no adverse fetal outcomes
    Reactions Weekly, 2013, 1444 (1) : 2 - 2
  • [8] Ondansetron in Pregnancy and Risk of Adverse Fetal Outcomes EDITORIAL COMMENT
    Pasternak, Bjorn
    Svanstrom, Henrik
    Hviid, Anders
    OBSTETRICAL & GYNECOLOGICAL SURVEY, 2013, 68 (07) : 508 - 510
  • [9] Ondansetron in Pregnancy and Risk of Adverse Fetal Outcomes (vol 368, pg 814, 2013)
    Pasternak, Bjorn
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (22): : 2146 - 2146
  • [10] Reducing disparities in adverse pregnancy outcomes in the United States
    Shah, Lochan M.
    Varma, Bhavya
    Nasir, Khurram
    Walsh, Mary Norine
    Blumenthal, Roger S.
    Mehta, Laxmi S.
    Sharma, Garima
    AMERICAN HEART JOURNAL, 2021, 242 : 92 - 102
12345